Loading...
Market
What will be the change in Sage Therapeutics' cash balance by the end of Q2 2025?
2
Resolution / Starting Odds
Increase to over $600M • 25%
Remain between $500M and $600M • 25%
Decrease to between $400M and $500M • 25%
Decrease below $400M • 25%
Sage Therapeutics' financial statements or earnings reports
Story
Biogen Offers $469 Million for Sage Therapeutics at $7.22 Per Share, a 30% Premium
Jan 10, 2025, 11:25 PM
Biogen Inc. has made an unsolicited nonbinding offer to acquire Sage Therapeutics Inc. for $7.22 per share, valuing the company at approximately $469 million. The offer represents a 30% premium over Sage's closing price, leading to a 34% increase in Sage's stock price during after-hours trading. Sage, known for developing Zurzuvae, the first and only oral drug approved by the FDA for postpartum depression, has confirmed receipt of the proposal. The acquisition comes after Sage has experienced setbacks and a decline in its market value, with recent financials showing a cash burn of about $110 million in expenses against $11 million in revenue for the third quarter of 2024 (3Q24), and a cash balance of approximately $560 million at the end of September 2024.
View original story
Similar markets
$5 billion to $6 billion • 25%
More than $7 billion • 25%
$6 billion to $7 billion • 25%
Less than $5 billion • 25%
Above $5 billion • 25%
Below $3 billion • 25%
$3 billion to $4 billion • 25%
$4 billion to $5 billion • 25%
$2.5 billion or more • 25%
$2 billion • 25%
More than $2 billion but less than $2.5 billion • 25%
Less than $2 billion • 25%
Less than 1,873 BTC • 25%
More than 2,000 BTC • 25%
1,874 to 2,000 BTC • 25%
1,873 BTC • 25%
Increase by less than 10% • 25%
Increase by more than 30% • 25%
Increase by 10-30% • 25%
Decrease • 25%
No significant change • 25%
Decrease in revenue • 25%
Significant increase in revenue • 25%
Moderate increase in revenue • 25%
$20-$30 • 25%
$10-$20 • 25%
Below $10 • 25%
Above $30 • 25%
More than $6 billion • 25%
$5 billion to $6 billion • 25%
$4 billion to $5 billion • 25%
Less than $4 billion • 25%
Unknown • 25%
Increased • 25%
Decreased • 25%
Unchanged • 25%